Application/Category:
Need Training?
Build a solid foundation in science, formulation and product development—find out more!
Most Popular in:
Skin Care
New Data Shows Improvement, Long-Term Response in Psoriasis Treatment
Posted: March 10, 2006
page 2 of 2
In November 2005, Centocor, Inc. announced that the U. S. Food and Drug Administration (FDA) accepted its filing of a supplemental Biologics License Application (sBLA) for the use of the product in the treatment of moderate to severe plaque psoriasis. The acceptance of the sBLA file for psoriasis follows the September 2005 European Commission approval of the product for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or psoralen plus ultraviolet light A (PUVA). The product is approved in the U.S. and the European Union (EU) for the treatment of active psoriatic arthritis.
